Acclimatization Mechanisms During Ascent to 7500m - Full Text View

Sponsor:	University of Zurich
Collaborator:	Swiss National Science Foundation
Information provided by:	University of Zurich
ClinicalTrials.gov Identifier:	NCT00603122

Purpose

The trial evaluates the role of ascent protocol on acute mountain sickness and cardio-respiratory physiology during an ascent to Muztagh Ata (7546m). Two groups of mountaineers ascend with different acclimatization time to the summit. The prevalence and severity of symptoms of acute mountain sickness are evaluated along with physiologic variables.

Condition	Intervention
Acute Mountain Sickness	Behavioral: ascent protocol

Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention
Official Title:	Acclimatization Mechanisms During Ascent to 7500m. Effects of Ascent Protocol on Acute Mountain Sickness and Cardiorespiratory Physiology

Further study details as provided by University of Zurich:

Primary Outcome Measures:

acute mountain sickness [ Time Frame: during ascent ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

mountaineering success, oxygen saturation, breathing pattern [ Time Frame: during ascent ] [ Designated as safety issue: No ]

Enrollment:	37
Study Start Date:	March 2005
Study Completion Date:	December 2005
Primary Completion Date:	December 2005 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1 fast ascent	Behavioral: ascent protocol ascent protocol for the two groups has different acclimatization time
Active Comparator: 2 slow ascent	Behavioral: ascent protocol ascent protocol for the two groups has different acclimatization time

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Healthy, physically fit subject
Mountaineering experience

Exclusion Criteria:

Any type of cardiac or respiratory disease
Regular intake of any medication
History of high altitude pulmonary oedema
Severe acute mountain sickness at altitudes below 3500m or high altitude cerebral oedema.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00603122

Sponsors and Collaborators

University of Zurich

Swiss National Science Foundation

Investigators

Principal Investigator:

Konrad E Bloch, MD

Pulmonary Division, University Hospital of Zurich, Zurich, Switzerland

More Information

Publications:

Bloch KE, Turk AJ, Maggiorini M, Hess T, Merz T, Bosch MM, Barthelmes D, Hefti U, Pichler J, Senn O, Schoch OD. Effect of ascent protocol on acute mountain sickness and success at Muztagh Ata, 7546 m. High Alt Med Biol. 2009 Spring;10(1):25-32.

Bloch KE, Latshang T, Turk AJ, Hess T, Hefti U, Merz TM, Bosch MM, Barthelmes D, Pichler Hefti J, Maggiorini M, Schoch OD. Nocturnal Periodic Breathing During Acclimatization at Very High Altitude at Mt. Muztagh Ata (7546m). Am J Respir Crit Care Med. 2010 May 4; [Epub ahead of print]

Responsible Party:	Konrad E. Bloch, University Hospital Zurich
ClinicalTrials.gov Identifier:	NCT00603122 History of Changes
Other Study ID Numbers:	EK-1189, SNSF 3200B0-108300
Study First Received:	January 15, 2008
Last Updated:	May 25, 2010
Health Authority:	Switzerland: Swissmedic

Keywords provided by University of Zurich:

altitude illness
hypoxia

Additional relevant MeSH terms:

Altitude Sickness
Respiration Disorders
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on February 12, 2012